Malottki, K <br/><br/>
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  Mar 2011 
 - 1-278 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review; Systematic Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta15140  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept<br/>Adalimumab<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Antibodies, Monoclonal, Murine-Derived--economics<br/>Antirheumatic Agents--economics<br/>Arthritis, Rheumatoid--drug therapy<br/>Etanercept<br/>Humans<br/>Immunoconjugates--economics<br/>Immunoglobulin G--economics<br/>Infliximab<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Rituximab<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>United Kingdom